Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in patients with peripheral arterial occlusive disease (PAOD) and intermittent claudication.

Trial Profile

A multi-centre, randomized, placebo-controlled, double-blind trial to assess the efficacy and safety of nitroglycerin sublingual powder on walking distance in a scheduled forced titration design in patients with peripheral arterial occlusive disease (PAOD) and intermittent claudication.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jan 2019

At a glance

  • Drugs Nitroglycerin (Primary)
  • Indications Intermittent claudication; Peripheral arterial occlusive disorders
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Pohl-Boskamp
  • Most Recent Events

    • 04 Jan 2019 Status changed from recruiting to completed.
    • 15 Feb 2018 Planned number of patients changed from 60 to 100.
    • 24 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top